Jacobio completes first patient assay of CD73 mAb JAB-BX102 in China
BEIJING, September 2, 2022 /PRNewswire/ — Jacobio Pharma (1167.HK) announced that it has completed the first assay of its in-house R&D monoclonal antibody CD73 drug candidate JAB-BX102 in a Phase I/IIa clinical trial for patients with advanced solid tumors. .
This is a Phase I/IIa multicenter open-label clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary evidence of antitumor activity of JAB-BX102 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors.
JAB-BX102 is Jacobio’s first large molecule program to enter the clinical phase. “The landscape of cancer treatment is increasingly complicated, combination therapies between different modalities are needed. Jacobio’s pipeline focuses on unmet clinical needs and aims to bring hope to more patients through therapies As an important immuno-oncology target, CD73 has the potential to be used in combination with multiple immuno-oncology therapies, such as PD-1/PD-L1 antibody and STING agonist, to relieve immunosuppression of the tumor microenvironment, stimulate the proliferation and activation of immune effector cells, enhance tumor immunity and play a synergistic role. Jacobio is developing CD73 STING iADC JAB-X1800.” Said Dr. Yinxiang Wang, Chairman and CEO of Jacobio.
JAB-BX102 is a humanized, anti-CD73 monoclonal antibody. CD73 is a protein that plays a key role in the adenosine pathway, and its inhibition has broad therapeutic potential for tumors that depend on an active adenosine pathway. Combination treatment of JAB-BX102 with immune checkpoint drugs such as PD-(L)1 (anti-PD-1 or anti-PD-L1) antibodies may result in synergistic antitumor efficacy. There are no anti-CD73 antibodies currently approved for the treatment of cancer. Preclinical data suggests that JAB-BX102 has a dose-activity advantage and has the potential to benefit patients with solid tumors.
Jacobio Pharma (1167.HK) is committed to developing and delivering new and innovative products and solutions to improve people’s health. Our pipeline revolves around new molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a world leader recognized for its impact in drug R&D with our partners. Jacobio has R&D centers in beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC platform.
Please visit us at www.jacobiopharma.com